SBT 6290
Alternative Names: SBT-6290Latest Information Update: 14 Nov 2022
At a glance
- Originator Silverback Therapeutics
- Developer ARS Pharmaceuticals
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Toll-like receptor 8 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 08 Nov 2022 Silverback Therapeutics has been acquired and merged into ARS Pharmaceuticals
- 12 Apr 2022 Silverback withdraws its phase I/II trial in Solid tumours (Late-stage disease, Metastatic disease, Monotherapy, Combination therapy) in USA due to sponsor decision based on strategic re-alignment (NCT05234606)
- 31 Mar 2022 Discontinued - Phase-I/II for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in USA (SC)